Fundraising Fox

Roivant

2 known investors

Roivant develops pharmaceutical medicines and medical technologies through a subsidiary model called "Vants," focused on accelerating the development and commercialization of treatments for dermatology and other therapeutic areas. The company operates as a biopharmaceutical holding with multiple focused companies advancing drug candidates through clinical trials and commercial launch.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

VR
Vivek Ramaswamy
IC
Iván Cornella-TaracidoVice President of Translational Chemical Biology

Investors · 2

Commonweal VenturesNew York · $500K – $2.5M
SoftBank Vision FundLondon

In the news

Roivant Sciences (ROIV) – Research Analysts’ Recent Ratings Updates - Markets Dailythemarketsdaily.com · Aug 2026BofA raises Roivant Sciences stock price target on trial outlook By Investing.cominvesting.com · Jul 2026Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding - Simply Wall St Newssimplywall.st · May 2026

Frequently asked questions

What does Roivant do?
Roivant develops pharmaceutical medicines and medical technologies through a subsidiary model called "Vants," focused on accelerating the development and commercialization of treatments for dermatology and other therapeutic areas. The company operates as a biopharmaceutical holding with multiple focused companies advancing drug candidates through clinical trials and commercial launch.
Who founded Roivant?
Roivant was founded by Vivek Ramaswamy.
Who are Roivant's investors?
Roivant's investors include Commonweal Ventures, SoftBank Vision Fund.